Flow Pharma

Executive Summary

Flow Pharma is a private biotechnology company based in San Francisco, founded in 2015, focused on developing a novel class of T-cell stimulating immunotherapies for cancer and viral diseases. Its core technology is a patented, stable dry-powder delivery system for synthetic peptide vaccines, which eliminates the need for viral vectors, DNA, or RNA. This approach aims to induce potent and durable T-cell responses, potentially offering advantages in stability, scalability, and safety over existing vaccine platforms. The company's platform has broad applicability across oncology and infectious diseases, though it remains in early preclinical stages with no disclosed funding or partnership milestones. Despite the innovative delivery mechanism, the lack of publicly available data on specific pipeline programs or clinical timelines makes it difficult to assess near-term progress. Continued development and validation of the platform in relevant disease models will be critical for attracting investment and advancing toward clinical trials.

Upcoming Catalysts (preview)

• 2026Preclinical Proof-of-Concept Data for Lead Candidate40% success
• 2027Strategic Partnership or Licensing Agreement20% success